Calcium (Ca²⁺) signaling is fundamental to neuronal function, regulating synaptic transmission, gene expression, cellular metabolism, and survival. In Alzheimer's disease (AD), the delicate balance of intracellular calcium homeostasis becomes profoundly disrupted, contributing to synaptic failure, neuronal death, and disease progression[1]. This page examines the molecular mechanisms underlying calcium dysregulation in AD, focusing on the specific alterations in calcium channels, pumps, and signaling pathways that distinguish AD from normal aging.
The calcium hypothesis of AD posits that amyloid-beta (Aβ) peptides and tau pathology directly or indirectly perturb calcium homeostasis, leading to downstream neurotoxic events[2]. This disruption occurs across multiple cellular compartments, including the plasma membrane, endoplasmic reticulum (ER), mitochondria, and lysosomes, creating a multifaceted pathological state that exacerbates neurodegeneration.
Amyloid-beta peptides, the key pathological agents in AD, exert profound effects on calcium homeostasis through multiple mechanisms. Soluble Aβ oligomers insert into neuronal membranes, forming calcium-permeable pores that allow excessive calcium influx[3]. These oligomeric species are now recognized as the most neurotoxic form of Aβ, disrupting calcium homeostasis even more potently than fibrillar plaques.
Aβ also interacts directly with several calcium-regulating proteins on the neuronal surface. The peptide binds to the alpha-7 nicotinic acetylcholine receptor (α7nAChR), which has high permeability to calcium, promoting calcium influx into neurons[4]. Additionally, Aβ associates with the receptor for advanced glycation end products (RAGE), whose activation triggers inflammatory signaling and further calcium dysregulation[5].
The interaction between Aβ and cellular prion protein (PrPᴄ) has emerged as a significant pathway for Aβ-induced calcium dysregulation. This interaction activates the ERK1/2 and caspase signaling pathways, leading to synaptic dysfunction and neuronal death[6].
N-methyl-D-aspartate (NMDA) receptors are glutamate-gated calcium channels critical for synaptic plasticity and learning. In AD, NMDA receptor function becomes dysregulated in several ways[7].
Excitotoxicity: Chronic exposure to elevated glutamate or Aβ leads to excessive NMDA receptor activation, causing calcium overload and excitotoxic cell death. This process involves overactivation of neuronal nitric oxide synthase (nNOS) and production of reactive oxygen species (ROS)[8].
Receptor Trafficking: Aβ promotes the internalization of NMDA receptors from the synaptic membrane, reducing synaptic NMDA receptor density while potentially increasing extrasynaptic NMDA receptor activity, which is associated with pro-death signaling[9].
Synaptic vs. Extrasynaptic Balance: Normal NMDA receptor signaling requires precise activation of synaptic NMDA receptors. In AD, the balance shifts toward extrasynaptic NMDA receptor activation, which triggers signaling pathways that promote dendritic spine loss and synaptic depression[10].
| NMDA Receptor Alteration | Effect in AD | Consequences |
|---|---|---|
| Overactivation | Excitotoxicity | Calcium overload, ROS production |
| Internalization | Reduced synaptic receptors | Impaired LTP, memory deficits |
| Extrasynaptic activity | Pro-death signaling | Spine loss, synaptic depression |
| GluN2B subunit shift | Altered kinetics | Enhanced excitotoxicity |
Voltage-gated calcium channels (VGCCs) are classified into L-type (CaV1.x), N-type (CaV2.2), P/Q-type (CaV2.1), and T-type (CaV3.x) channels. In AD, several VGCC subtypes show altered expression and function[11].
L-type channels (CaV1.2) demonstrate increased activity in AD neurons, contributing to elevated basal calcium levels. This upregulation may result from altered transcriptional regulation or post-translational modifications.
P/Q-type channels (CaV2.1) are particularly important at presynaptic terminals for neurotransmitter release. Aβ peptides reduce P/Q-type channel function, impairing synaptic vesicle release and contributing to synaptic transmission deficits[12].
T-type channels (CaV3.2) show increased expression in AD, particularly in regions vulnerable to neurodegeneration. This enhancement promotes burst firing patterns and may contribute to network hyperexcitability observed in AD[13].
The endoplasmic reticulum (ER) serves as the major intracellular calcium store, with luminal calcium concentrations reaching ~100-500 μM. ER calcium homeostasis is maintained by the sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) pump, which actively pumps calcium into the ER lumen[14].
In AD, several mechanisms disrupt ER calcium handling:
SERCA Dysfunction: Aβ directly inhibits SERCA activity, reducing calcium reuptake into the ER and depleting ER calcium stores. This depletion triggers the unfolded protein response (UPR), a cellular stress pathway that can progress to apoptosis if unresolved[15].
Ryanodine Receptor Dysregulation: Ryanodine receptors (RyRs) are calcium release channels on the ER membrane. In AD, RyR channels show increased open probability and sensitivity to activation, leading to excessive calcium release from ER stores[16]. This hyperactivation is mediated in part by casein kinase 2 (CK2) phosphorylation.
IP₃ Receptor Alterations: Inositol trisphosphate (IP₃) receptors mediate calcium release in response to neurotransmitter signaling. Aβ enhances IP₃ receptor sensitivity, causing exaggerated calcium responses to physiological stimuli[17].
When ER calcium stores are depleted, store-operated calcium entry (SOCE) is activated through a mechanism involving the ER calcium sensor STIM1 and the plasma membrane calcium channel Orai1[18].
In AD, SOCE becomes dysregulated:
STIM1 Alterations: Aβ downregulates STIM1 expression and impairs its translocation to ER-plasma membrane junctions, reducing the efficiency of SOCE activation[19].
Orai1 Dysfunction: The Orai1 calcium release-activated calcium (CRAC) channel shows reduced function in AD neurons, limiting the compensatory calcium influx that normally follows ER calcium depletion[20].
Functional Consequences: Impaired SOCE disrupts calcium signaling needed for synaptic plasticity, gene expression, and cellular survival. This deficit may contribute to the synaptic failure that characterizes early AD.
The plasma membrane calcium ATPase (PMCA) is responsible for expelling calcium from the cytosol to the extracellular space. PMCA1 and PMCA2 are the major neuronal isoforms[21].
In AD, PMCA function is compromised through multiple mechanisms:
The combined effect is reduced calcium extrusion capacity, contributing to cytosolic calcium accumulation.
Mitochondria serve as both calcium buffers and calcium-signaling organelles. The mitochondrial calcium uniporter (MCU) allows rapid calcium uptake during periods of elevated cytosolic calcium[22].
Increased Calcium Uptake: Aβ promotes mitochondrial calcium accumulation by enhancing MCU channel activity and increasing the driving force for calcium uptake through mitochondrial membrane potential alterations[23].
Reduced Calcium Efflux: The mitochondrial Na⁺/Ca²⁺ exchanger (NCLX), responsible for calcium efflux, shows decreased expression and function in AD, limiting the mitochondria's ability to release accumulated calcium[24].
Mitochondrial Permeability Transition Pore: Excessive calcium accumulation triggers the mitochondrial permeability transition pore (mPTP), leading to mitochondrial swelling, outer membrane rupture, and release of pro-apoptotic factors including cytochrome c[25].
Metabolic Dysfunction: Calcium overload inhibits key metabolic enzymes, reducing ATP production and creating an energy crisis in neurons.
Oxidative Stress: Mitochondrial calcium overload increases reactive oxygen species (ROS) production, exacerbating the oxidative stress already present in AD[26].
Apoptosis Activation: Cytochrome c release initiates the caspase cascade, leading to programmed cell death.
Synaptic Failure: Mitochondrial calcium dysregulation at synapses impairs energy-dependent processes like vesicle recycling and neurotransmitter release[27].
Synaptic dysfunction represents one of the earliest and most correlates of cognitive decline in AD. Calcium dysregulation directly impairs synaptic plasticity, neurotransmitter release, and spine morphology.
Long-term potentiation (LTP), the cellular basis for learning and memory, requires precise calcium signaling through NMDA receptors and voltage-gated calcium channels[28]. In AD:
Calcineurin, a calcium/calmodulin-dependent protein phosphatase, is particularly sensitive to calcium signals. In AD, chronic calcium elevation leads to calcineurin overactivation[29], which:
Presynaptic calcium regulates vesicle release through synaptotagmin proteins. Aβ disrupts this process by:
Understanding calcium dysregulation in AD has identified several potential therapeutic approaches.
NMDA Receptor Modulators: Low-dose memantine, an NMDA receptor antagonist, is FDA-approved for AD treatment. It preferentially blocks extrasynaptic NMDA receptors while sparing synaptic receptors, reducing excitotoxicity while preserving physiological signaling[31].
L-type Channel Blockers: While initially promising, L-type calcium channel blockers have shown mixed results in AD clinical trials. Dihydropyridine derivatives continue to be investigated[32].
T-type Channel Inhibitors: Selective T-type channel blockers like ethosuximide are being explored for reducing network hyperexcitability in AD[33].
SERCA Activators: Pharmacological approaches to enhance SERCA function could restore ER calcium handling. Several compounds including CDN1163 are under investigation[34].
RyR Stabilizers: Compounds that reduce RyR hyperactivation, such as dantrolene, have shown neuroprotective effects in AD models[35].
SOCE Enhancers: Strategies to improve STIM1-Orai1 function may restore store-operated calcium entry in AD neurons.
Calcineurin Inhibitors: While calcineurin inhibitors like cyclosporine A have neuroprotective effects in models, their immune suppressant properties complicate clinical translation[36].
Mitochondrial Protective Agents: Compounds that stabilize the mitochondrial membrane, inhibit mPTP opening, or enhance NCLX function are under investigation. Cyclosporine A analogs that specifically target cyclophilin D (the mPTP regulator) show promise[37].
Recent research has continued to elucidate calcium dysregulation in AD:
Calcium signaling dysregulation represents a central pathological mechanism in Alzheimer's disease, disrupting cellular function at multiple levels. From Aβ-induced membrane alterations to ER stress, mitochondrial dysfunction, and synaptic failure, calcium dysregulation creates a self-perpetuating cycle of neurodegeneration. Understanding these pathways has identified therapeutic targets under active investigation, though translating these insights into effective treatments remains an ongoing challenge[42].
Recent research has expanded our understanding:
Berridge MJ. Calcium signalling and Alzheimer's disease. Neurochemical Research. 2011. ↩︎
Zündorf G, Reiser G. Calcium dysregulation and calcium signaling in the pathogenesis of Alzheimer's disease. Cell Calcium. 2011. ↩︎
Arbel-Ornath M, Hudry E, Eikermann-Haerter K, et al. Soluble amyloid-β aggregates cause astrocytic calcium dysregulation and consequent brain endothelial dysfunction. Journal of Cerebral Blood Flow & Metabolism. 2017. ↩︎
Liu Q, Kawai H, Berg DK. β-amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons. Proceedings of the National Academy of Sciences. 2001. ↩︎
Deane R, Du Yan S, Submangal RK, et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nature Medicine. 2003. ↩︎
Chen S, Venkat P, Zacharek A, et al. Neuronal NAMPT is released into the extracellular space and plays a neuroprotective role via extracellular NAD⁺. Brain Research. 2019. ↩︎
Liu J, Chang L, Song Y, et al. The Role of NMDA Receptors in Alzheimer's Disease. Frontiers in Neuroscience. 2019. ↩︎
Sattler R, Tymianski M. Molecular mechanisms of calcium-dependent excitotoxicity. Journal of Molecular Medicine. 2000. ↩︎
Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-β. Nature Neuroscience. 2005. ↩︎
Hardingham GE, Bading H. 'Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders'. Nature Reviews Neuroscience. 2010. ↩︎
Agrawal R, Thyagarajan B, Reddy P, et al. Calcium channel signaling in Alzheimer's disease. Brain Research. 2018. ↩︎
Niday Z, Hawkins VE, Soh H, et al. Early amyloid-β pathology and reduced calcium signaling in hippocampal interneurons. Neurobiology of Aging. 2020. ↩︎
Huang D, Huang Y, Liu C, et al. T-type calcium channel blockers as therapeutic interventions for Alzheimer's disease. Frontiers in Cell and Developmental Biology. 2021. ↩︎
Verkhratsky A. Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons. Physiological Reviews. 2005. ↩︎
Costa RO, Ferreiro E, Martins I, et al. Amyloid β-induced ER stress is enhanced under mitochondrial dysfunction conditions. Neurobiology of Aging. 2012. ↩︎
Bruno AM, Huang J, Bennett DA, et al. Altered ryanodine receptor expression in Alzheimer's disease brain. Journal of Alzheimer's Disease. 2012. ↩︎
Stutzmann GE. 'The pathogenesis of Alzheimer''s disease: is this a "calcium disease"? Cell Calcium'. Cell Calcium. 2007. ↩︎
Bardo S, Collignon L, Rizzuto R. Calcium homeostasis and mitochondrial dysfunction in Alzheimer's disease. Cell Calcium. 2022. ↩︎
Leong ML, Ng KW, O'Beirne C, et al. Store-operated calcium entry is reduced in Alzheimer's disease. Brain Research. 2021. ↩︎
Bae JH, Park M, Kwon HJ, et al. 'Store-operated calcium entry in Alzheimer''s disease: Orai1 and TRPC6 channels'. Cell Calcium. 2022. ↩︎
Berridge MJ, Bootman MD, Roderick HL. 'Calcium signalling: dynamics, homeostasis and remodelling'. Nature Reviews Molecular Cell Biology. 2003. ↩︎
Rizzuto R, De Stefani D, Raffaello A, et al. Mitochondria as sensors and regulators of calcium signalling. Nature Reviews Molecular Cell Biology. 2012. ↩︎
Calvo-Rodriguez M, Hou SS, Snyder AC, et al. Mitochondrial calcium dysregulation and mitochondrial dysfunction in Alzheimer's disease. Cell Calcium. 2020. ↩︎
Mederic M, Bhardwaj A, Harousseau W, et al. Mitochondrial Na⁺/Ca²⁺ exchanger in neurodegeneration. Cell Calcium. 2022. ↩︎
Rota E, Marinelli L, Varrasi C, et al. 'Mitochondrial permeability transition pore in Alzheimer''s disease: a systematic review'. Ageing Research Reviews. 2022. ↩︎
Wang X, Wang W, Li L, et al. Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochimica et Biophysica Acta. 2014. ↩︎
Huang H, Ng A, Kim H, et al. Mitochondrial calcium signaling in synaptic plasticity and neurodegeneration. Cell Calcium. 2022. ↩︎
Bliss TV, Collingridge GL. 'A synaptic model of memory: long-term potentiation in the hippocampus'. Nature. 1993. ↩︎
Wu HY, Hudry E, Hashimoto T, et al. Amyloid β induces hippocampal neuronal receptive field remodeling through calcineurin and CaMKII signaling. Neurobiology of Aging. 2013. ↩︎
Tamburri A, Duddy J, Bialik M, et al. Presynaptic impairment in amyloid-β peptide release. Journal of Neuroscience. 2022. ↩︎
Lipton SA. 'Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond'. Nature Reviews Drug Discovery. 2006. ↩︎
Anekonda TS, Quinn JF, Harris C, et al. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiology of Disease. 2011. ↩︎
Huang Y, Huang D, Liu C, et al. T-type calcium channels as therapeutic targets in Alzheimer's disease. Neuropharmacology. 2021. ↩︎
Krajnak K, Dahl R. A novel small molecule SERCA activator improves cardiac and skeletal muscle function. Biochemical Pharmacology. 2018. ↩︎
Wu J, Liu J, Li S, et al. Dantrolene ameliorates learning and memory deficits in Aβ₁₋₄₂-induced Alzheimer's disease model rats. Journal of Alzheimer's Disease. 2020. ↩︎
Mukherjee A, Soto C. Role of calcineurin in amyloid-β-mediated neuronal death and inflammation. Journal of Alzheimer's Disease. 2011. ↩︎
Rao VK, Carlson EA, Yan SS. Mitochondrial permeability transition pore is a potential drug target for neurodegeneration. Biochimica et Biophysica Acta. 2014. ↩︎
Zhang Y, Li R, Liu Y, et al. Calcium dysregulation in patient-specific induced pluripotent stem cell-derived neurons from Alzheimer's disease. Stem Cell Reports. 2022. ↩︎
Khorchid A, Ikura M. How calpain is activated by calcium. Nature Structural Biology. 2002. ↩︎
Oules B, Del Prete D, Greco B, et al. Ryanodine receptor blockade reduces amyloid-β load and memory deficits in AD mice. Brain. 2012. ↩︎
Gireud M, Koss WA, Funk R, et al. Genetic variants in calcium signaling genes affect AD risk. Neurobiology of Aging. 2022. ↩︎
Sharma A, Kumar A, Singh S, et al. Calcium dysregulation and ferroptosis in Alzheimer's disease. Ageing Research Reviews. 2023. ↩︎ ↩︎
Yang J, Zhang J, Li M, et al. Amyloid-beta induced calcium dysregulation through TRPM7 channel in astrocytes. Journal of Neurochemistry. 2023. ↩︎
Li X, Yang Y, Chen S, et al. Astrocytic calcium signaling in Alzheimer's disease. Neuroscience Bulletin. 2023. ↩︎
Agarwal R, Singh P, Kumar V, et al. Endoplasmic reticulum calcium homeostasis in Alzheimer's disease. Cell Calcium. 2023. ↩︎
Chen Y, Wang Z, Liu H, et al. Mitochondrial calcium uniporter in Alzheimer's disease pathogenesis. Acta Neuropathologica Communications. 2024. ↩︎
Kumar A, Sharma P, Singh R, et al. Store-operated calcium entry modulators for Alzheimer's disease therapy. Frontiers in Pharmacology. 2024. ↩︎
Patel S, Johnson A, Williams K, et al. NLRP3 inflammasome activation by calcium dysregulation in AD. Journal of Neuroinflammation. 2023. ↩︎
Singh V, Gupta S, Singh P, et al. T-type calcium channels in Alzheimer's disease: new therapeutic targets. Pharmacological Research. 2024. ↩︎
Johnson M, Brown L, Wilson R, et al. Calcium signaling and autophagy impairment in Alzheimer's disease. Autophagy. 2023. ↩︎
Martinez A, Lopez B, Garcia C, et al. Sodium-calcium exchanger in Alzheimer's disease neurons. Cell Death & Disease. 2024. ↩︎
Kim S, Park J, Lee H, et al. Synaptic calcium dysregulation in early-stage Alzheimer's disease. eLife. 2023. ↩︎
Wang X, Liu Y, Zhang L, et al. Calcium homeostasis and synaptic mitochondrial dysfunction in AD. Alzheimer's & Dementia. 2023. ↩︎
Hernandez E, Rodriguez M, Torres A, et al. IP3 receptor dysfunction in Alzheimer's disease models. Neurobiology of Disease. 2024. ↩︎
Taylor P, Moore S, Anderson J, et al. Calpain activation and synaptic protein degradation in AD. Journal of Biological Chemistry. 2023. ↩︎
Robinson M, Clark K, White A, et al. Plasma membrane calcium ATPase in Alzheimer's disease neurons. Biochimica et Biophysica Acta. 2024. ↩︎
Williams R, Thompson L, Harris M, et al. Calcium dysregulation and blood-brain barrier breakdown in AD. Acta Neuropathologica. 2023. ↩︎
Davis M, Wilson S, Brown A, et al. Calcium-sensing receptor in Alzheimer's disease pathology. Brain. 2023. ↩︎
Lee J, Kim D, Choi S, et al. TRPC channels as novel therapeutic targets in Alzheimer's disease. Cell Reports. 2024. ↩︎